2000
DOI: 10.1046/j.1365-4362.2000.00964.x
|View full text |Cite
|
Sign up to set email alerts
|

An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
21
0

Year Published

2002
2002
2021
2021

Publication Types

Select...
5
2

Relationship

1
6

Authors

Journals

citations
Cited by 37 publications
(21 citation statements)
references
References 110 publications
(238 reference statements)
0
21
0
Order By: Relevance
“…Prophylactic regimens using ketoconazole include 200 mg given on 3 consecutive days every month 20 or a single dose of 400 mg taken once a month. 21,22 Topical therapies have been used as a prophylactic, but patient compliance is lower, and no controlled studies have been reported in the literature, to our knowledge.…”
Section: Commentmentioning
confidence: 99%
“…Prophylactic regimens using ketoconazole include 200 mg given on 3 consecutive days every month 20 or a single dose of 400 mg taken once a month. 21,22 Topical therapies have been used as a prophylactic, but patient compliance is lower, and no controlled studies have been reported in the literature, to our knowledge.…”
Section: Commentmentioning
confidence: 99%
“…In Goiania city, Brazil, these same etiological agents have been recovered in studies of COSTA et al 6,7 . Antifungal agents such as triazoles (itraconazole, fluconazole), imidazole (ketoconazole), allylamine (terbinafine) and griseofulvin have been reported to have substantial activity in dermatophytosis 16,17 . However, infections due to dermatophytes are often associated with relapses after cessation of therapy 20 .…”
Section: Introductionmentioning
confidence: 99%
“…Several therapeutic regimens are reported to have activity in these fungi and are therefore being used in treating it 9,17 . Although in the last few years, there has been a steady introduction of new drugs by either modification of pre-existing or entirely new chemical classes of antimycotics, there has also been an increased interest in clinically relevant susceptibility testing 16 .…”
Section: Introductionmentioning
confidence: 99%